antigen level modified adjuvanted trivalent subunit influenza vaccine

**Antigen level modified adjuvanted trivalent subunit influenza vaccine** is an investigational MF59-adjuvanted, inactivated trivalent influenza subunit vaccine formulation developed in the Seqirus seasonal influenza vaccine program. In the completed Phase 1 study NCT02126761, this was the Group 3 antigen-only modified formulation, with the usual aggregate hemagglutinin antigen amount doubled from 45 micrograms to 90 micrograms across the A/H1N1, A/H3N2, and influenza B components while retaining MF59 adjuvantation. It was evaluated for safety and immunogenicity in adults aged 65 years and older and is distinct from the licensed standard-antigen-dose Fluad formulation. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT02126761/))

Other names

antigen level modified adjuvanted, trivalent subunit influenza vaccine